Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Year-End Report October – December 2021

(Oslo, 18 February 2022) Genetic Analysis AS (“GA” or “the Company”) hereby publishes the year-end report for the period 1 October – December 31, 2021. The year-end report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.Genetic Analysis CEO Ronny Hermansen comments:“The year of 2021 has passed, and we can look back on an eventful year filled with milestones like an oversubscribed IPO, successful listing at Spotlight Stock Market, the signing of IMD as a new high-volume lab in Europe, and the receival of a research grant of

ORGANOCLICK AB (PUBL) PUBLISH YEAR END REPORT FOR 2021

"Sales of OrganoTex® more than doubled during the quarter, as with the full year. We expect the very strong sales growth of OrganoTex® to continue in 2022, driven by all our new customers and ongoing international expansion."Translation from CEO Mårten Hellbergs comments to the Interim Report. Q4, 1 October - 31 December 2021 The Group compared with 2020 » Net revenue amounted to SEK 17.95 (18.20) million » The gross margin (after variable costs) amounted to 43.8 (40.9) % » EBITDA amounted to SEK -7.65 (-6.03) million » Cash-flow from operating activities amounted to SEK -

Year-end report January – December 2021

The period in summary January 1 – December 31, 2021 –      The European Commission granted in August a Marketing Authorisation for Strangvac within the European Union. During September the Veterinary Medicines Directorate (VMD) of the United Kingdom also granted a Marketing Authorisation for Strangvac within the UK. –      In April Intervacc announced an exclusive distribution agreement with Dechra Pharmaceuticals PLC, to commercialize Strangvac in Europe, excluding the Nordic and Baltic countries where Intervacc will market and sell Strangvac directly. –      Intervacc was

Episurf Medical’s implants receive national regulatory approval in Hong Kong

Episurf Medical (NASDAQ: EPIS B) today announces that the Department of Health (Medical Device Division) in Hong Kong has approved the company’s implant technologies Episealer® Knee and Episealer® Talus for the Hong Kong market. Included in the approval is also the ankle device Talus Osteotomy Guide. The approval follows a review process.  “Previously we were able to act in this market thanks to our CE marked products, but it brought on various limitations. This national approval is important, and it will help us increase the market acceptance in the region even further”, says Michael

Notice of the Annual General Meeting of Ratos AB (publ)

Shareholders of Ratos AB (publ), reg.nr 556008-3585, are hereby invited to the Annual General Meeting to be held at Tuesday, March 22, 2022. The AGM will be conducted pursuant to so called mail-in procedures, meaning that no shareholders will attend the AGM in person or through proxy. Instead, shareholders can participate in the AGM by voting and submitting questions in advance pursuant to the instructions described below.In order to participate in the AGM, a shareholder shall:   a. be registered in the register of shareholders maintained by Euroclear Sweden AB as of Monday, March 14,

Veoneer publishes 2021 Annual and Sustainability Reports

Stockholm, Sweden, February 18, 2022: The automotive technology company Veoneer, Inc. (NYSE: VNE and SSE: VNE SDB), has filed its 2021 Annual Report on Form 10-K with the Securities and Exchange Commission (SEC).The 2021 Annual Report on Form 10-K is available at the SEC Edgar website: www.sec.gov and on Veoneer’s web site veoneer.com. Veoneer has also published its 2021 Sustainability Report and it is available on Veoneer’s web site veoneer.com. Annual Meeting of ShareholdersThe Board of Directors has set June 2, 2022 as the date for Veoneer's 2022 Annual Meeting of Shareholders to be

Attana has submitted a new patent application

Attana has filed a new patent application with claims for methods for assessing the neutralising potential of antibodies in biological samples. The invention is applicable in both of Attana´s business areas – Life Science and Diagnostics.Attana has filed a new patent application with several claims assessing the neutralising potential of antibodies or other biological entities in complex biological samples. The invention can be applied within diagnostics with the purpose to better determine the immunity of individuals based on several parameters, such as kinetics and titres of immune

Invitation to presentation of Sectra’s nine-month interim report 2021/2022

Linköping, Sweden – February 18, 2022 – International medical imaging IT and cybersecurity company Sectra  (STO: SECT B) invites investors, analysts, and the media to a presentation of the company’s nine-month report with President Torbjörn Kronander and CFO Mats Franzén.Publication of the interim report: 8:15 a.m. (CET) on March 9, 2022Report presentation: 10:00 a.m. (CET) on the same date To participate, follow the instructions on Sectra’s website investor.sectra.com/Q3report2122.The broadcast will also be made available on the same webpage after the conference.

Greenfood wins prestige business award - recognized for excellence in sustainability and innovation

Greenfood has won the Swedish business award, Företagsstjärnan (Star Company). The prize was awarded for Greenfood's outstanding performance in providing the market with sustainable, plant-based, affordable, and easily accessible food.“The climate is the most important issue of our time. How we produce our food and what we eat has major effects on the climate and the environment, so we must do everything we can to accelerate the transition to plant-based alternatives,” said David von Laskowski, President and CEO of Greenfood Group. Greenfood is one of northern Europe's leading players

Cell Impact reports fourth quarter results: increased sales

Cell Impact AB (Nasdaq First North GM: CI B) reports the following financial summary for the fourth quarter.· Revenues for the quarter amounted to SEK 21.0 million (8.9). Total revenues up to and including the fourth quarter amounted to SEK 81.8 million (29.3), which is growth of 179% for the entire year. · Operating result was SEK -25.7 million (-12.3). Total operating result was SEK -78.0 million up to and including the fourth quarter (-43.1). · The Group's result after financial items was SEK -26.5 million (-12.5). · Earnings per share attributable to the shareholders of the

Autoliv provides exterior airbag for Nuro’s autonomous vehicle

(Stockholm, Sweden, February 18, 2022) – Autoliv, Inc. (NYSE: ALV and SSE: ALIV.sdb), the worldwide leader in automotive safety systems, and Nuro, a leading autonomous vehicle company, are collaborating to ensure a high safety standard for Nuro’s new third-generation, production-grade autonomous delivery vehicle.As the most advanced zero-occupant vehicle designed by Nuro to date, the new flagship model features an exterior airbag by Autoliv which covers the front of the vehicle when inflated to protect other road users. The third-generation vehicle, simply called Nuro, is expected to scale

Arla Plast AB Year-end report 2021

Lower margins in the Quarter – Full year in line with financial objectivesOCTOBER – DECEmber 2021 · Sales volume declined by 2% to 5,503 tonnes (5,588). · Net sales increased by 13% to SEK 240.3 (211.9) million. The organic increase was 12%. · Operating profit declined by 63% to SEK 10.2 (27.4) million and adjusted operating profit by 69% to SEK 10.2 (33.2) million. · The operating margin declined to 4.2% (12.9%) and adjusted operating margin declined to 4.2% (15.7%).  · Profit for the period declined by 58% to SEK 8.4 (19.9) million. · Earnings per share before dilution

Adam & Albin to open Nori Bar in Bibliotekstan

Adam & Albin, together with multi-award-winning Josephine Sondlo, are to open Nori Bar in Birger Jarlspassagen. The new cocktail bar will open during spring in a space of almost 100 sqm with the ambition of further strengthening the prestigious Birger Jarlspassagen walkway as a vibrant meeting place at the heart of the city.Adam & Albin already run the Misshumasshu restaurant in Birger Jarlspassagen, which will now be completed by the cocktail bar with the celebrated chef duo and star bartender Josephine Sondlo. The inspiration for the Nori Bar concept is taken from the best New York bars

Viking Line: Year-End Report January - December 2021

Viking Line Abp                  YEAR-END REPORT              18.02.2022, 9.00 AM           January– December 2021 (compared to January–December 2020) · Sales amounted to EUR 258.2 M (EUR 188.8 M). · Other operating revenue was EUR 46.8 M (EUR 26.9 M). · Operating income totalled EUR 32.1 M (EUR -49.3 M). · Net financial items were EUR -3.8 M (EUR -3.6 M). · Income before taxes amounted to EUR 28.3 M (EUR -52.9 M). · Income after taxes totalled EUR 24.4 M (EUR -42.3 M). Outlook for the financial year 2022 The COVID-19 pandemic continues to have an impact on

Recipharm expands its advanced therapy medicinal products (ATMPs) offering into Virotherapies with the acquisition of Vibalogics

Recipharm, a global contract development and manufacturing organisation (CDMO), is continuing to build its service offerings in new biologic modalities through the acquisition of Vibalogics, a virotherapy CDMO and a portfolio company of Ampersand Capital Partners. Vibalogics holds a leading position in the manufacture of oncolytic viruses, viral vaccines and gene therapies, offering process and analytical development, manufacturing, testing and fill-finish services. Vibalogics is responding to the rapidly growing biopharmaceutical industry demand for specialized CDMO capabilities for the

Recipharm acquires Arranta Bio, a CDMO leader in advanced therapy medicinal products (ATMPs), to expand its biologics offering in the US

Recipharm, a leading global contract development and manufacturing organisation (CDMO), today announced the acquisition of Arranta Bio, a prominent advanced therapy CDMO. Under the stewardship of Mark Bamforth and backed by Ampersand Capital Partners, the company has established a strong service portfolio as a leader in delivering microbiome therapeutic products and mRNA clinical production capabilities. The acquisition forms a cornerstone of Recipharm’s strategy to provide innovative drug developers in the Biologics market with scientifically differentiated contract development and

MPC Container Ships ASA announces date for Q4 and twelve-month 2021 results

Oslo, 18 February 2022 - MPC Container Ships ASA (the "Company") will be releasing its fourth quarter 2021 report prior to market opening on Thursday 24 February 2022. The Company will host a webcast for the presentation of the Q4 2021 results commencing on Thursday 24 February 2022 at 15:00 hours CET / 09:00 hours EDT. The presentation will be made available on the Company’s webpage from 12:00 hours CET / 06:00 hours EDT. There will be a Q&A session after the presentation. The event is being streamed. It is recommended that you

Outokumpu – Transfer of the company’s own shares

Outokumpu OyjStock exchange releaseFebruary 18, 2022 at 9.00 am EETOutokumpu – Transfer of the company’s own shares Based on the decision of the Board of Directors of Outokumpu Oyj, a total of 137,760 Outokumpu’s shares net of taxes have been transferred as share rewards. 90,740 shares net of taxes were delivered to the personnel participating in the plan 2019–2021 and 47,020 shares net of taxes to the personnel participating in the plan 2021–2023 of the Restricted Share Pool. The share rewards were announced on February 8, 2022. Trading code: OUT1VNumber of shares: 137,760

Kemira Oyj: Announcement of manager’s transaction; Vice Chairman of the Board Matti Kähkönen has purchased 5,000 Kemira shares

Kemira Oyj, Managers' transactions, February 18, 2022 at 9.00 am (EET)Kemira Oyj: Announcement of manager’s transaction; Vice Chairman of the Board Matti Kähkönen has purchased 5,000 Kemira sharesKemira has received a notification from Matti Kähkönen, Vice Chairman of the Board, of a transaction made with its financial instrument, according to the EU Market Abuse Regulation.Detailed information about the transaction is given below.Person subject to the notification requirement:Name: Kähkönen, MattiPosition: Vice Chairman of the BoardIssuer: KEMIRALEI: 74370031Y7RK5H88CQ48

Gram Car Carriers ASA: Company update and presentation

Oslo, 18 February 2022 – Gram Car Carriers ASA (“GCC”), the world’s third largest car carrier tonnage provider, today provides a review of operations in Q4 2021 and an update on recent market developments and corporate events.  Key events:   · GCC established as a leading PCTS tonnage provider and listed on Euronext Growth from 31 January 2022 · Operating a fleet of 18 owned and 4 third-party vessels after completion of all transactions and vessel acquisitions · Q4 2021 average TCE revenue: Panamax USD 16,690, Mid-size USD 15,100 andDistribution fleet USD 10,540 · Long-

Green Landscaping Group acquires the Norwegian landscaping company Glenn Syvertsen AS

18 February 2022, 08:00 CET Green Landscaping Group AB (publ) has acquired Glenn Syvertsen AS with a turnover of approximately NOK 35 million. With the completion of the transaction, Green Landscaping Group, has made its 10th acquisition in Norway.Glenn Syvertsen AS is a company with a history from 2011 and has over the past 3 years experienced strong growth in the market around Oslo. Through quality deliveries, the company has developed with its customers and the company is expected to continue its growth in the coming years. - We have followed the company for a long time and in

Year-end Report January – December 2021

Significant events during the fourth quarter 2021 · The decided set-off issue increases the number of shares by 3,552,062. · The short-term loan facility is extended until the end of the first half of 2022. · The Board begins to seek successors to the CEO · The project director leaves his assignment Fourth quarter, 1 October – 31 December 2021 · Net income amounted to SEK 0 million (0) · Earnings after tax amounted to SEK -1.9 million (-2.1) · Investments during the period October – December totalled SEK 1.8 million (4.9) · Basic earnings per share were SEK -0.

BioArctic continues to build its commercial organization

Stockholm, February 18, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) continues to build the Nordic commercial organization ahead of a potential launch of the company’s lead drug candidate, lecanemab, in the Nordic region. During the spring 2022 several key roles will be added to the organization.Since 2005 BioArctic has a long-standing cooperation with the global pharmaceutical company Eisai regarding development and commercialisation of the drug candidate lecanemab (BAN2401) for the treatment of early Alzheimer’s disease. The development of lecanemab is driven by Eisai, which also

Irisity AB (publ) delivers a fourth quarter with strong growth and margins.

The CEO comments on the fourth quarter: Irisity’s net revenues amounted to 35.8 MSEK up by 244 percent with strong growth, paired with a gross margin of 83 percent. The monthly recurring revenue (MRR) was up by 57 percent on a quarterly basis. We continue to grow our business with improved margins and EBITDA. Reporting our first quarter after the transformative acquisition of Agent Vi (consolidated as of mid-October) we close larger deals internationally. This will have a positive effect on the MRR and cash flow going forward. The EBITDA and gross margin show strongest so far. Net

There are no items matching the current filter
There are no more items matching the current filter
Back to top